The National Health Care Institute has completed its assessment whether the product finerenon (Kerendia®) can be included in the Medicine Reimbursement System (GVS). Finerenon is indicated for the treatment of chronic kidney disease (CKD) (stage 3 or 4 with albuminuria) in adults with diabetes mellitus type 2 (DM2). The National Health Care Institute advises the Minister to include finerenon in the GVS with reimbursement conditions as described on this page.
Indication for which reimbursement is requested
Kerendia® is available as 10 mg and 20 mg film-coated tablets and is indicated for the treatment of patients with chronic kidney disease (CKD) (stage 3 or 4 with albuminuria) in adults with diabetes mellitus type 2 (DM2).
National Health Care Institute's advice
The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS, with the following reimbursement condition:
- Only for insured persons aged 18 and older with chronic kidney disease with diabetes mellitus type 2.